1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 19, 14/May/2026
  4. Article
Research Open Access
Like 0
Download

Abstract

BACKGROUND

Invasive type b (iHib) disease incidence in < 5-year-olds decreased after vaccine introduction but increased between 2011 and 2023 in the Netherlands. The National Immunisation Programme changed products in 2011 (from DTaP-IPV/Hib to DT3aP-HBV-IPV/Hib) and 2018 (to DT5aP-HBV-IPV-Hib) and schedule from 3 + 1 to 2 + 1 doses in 2020.

AIM

We aimed to estimate overall, product- and schedule-specific vaccine effectiveness (VE) against iHib disease to inform vaccination strategies.

METHODS

We conducted a matched case–control study extracting iHib cases born ≥ 2005 and aged 6–119 months from 2005–2023 national reference laboratory data. We selected 10 controls per case matched on birth date and sex from the population register and obtained vaccination data from the vaccination registry. Using conditional logistic regression, we estimated matched odds ratios (mOR) and VE among 6–10-month-olds (eligible only for the primary series) and 11–119-month-olds.

RESULTS

We included 250 iHib cases and 2,487 controls. Among children aged 11–119 months, VE against iHib of the full schedule was 96% (95% CI: 88–99), 95% (95% CI: 91–97) and 98% (95% CI: 94–99) for any DTaP-IPV/Hib, DT3aP-HBV-IPV/Hib and DT5aP-HBV-IPV-Hib, respectively. It was 97% (95% CI: 93–99) for 2 + 1, 96% (95% CI: 93–98) for 3 + 1 doses, and > 95% for the respective primary series. No differences in VE by time since vaccination were observed between products or schedules.

CONCLUSION

Changes in VE against iHib after recent product or schedule changes do not explain the increasing iHib incidence. The high VE supports pursuing optimal vaccination coverage.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.19.2500699
2026-05-14
2026-06-10
/content/10.2807/1560-7917.ES.2026.31.19.2500699
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/19/eurosurv-31-19-2.html?itemId=/content/10.2807/1560-7917.ES.2026.31.19.2500699&mimeType=html&fmt=ahah

References

  1. Slack MPE, Cripps AW, Grimwood K, Mackenzie GA, Ulanova M. Invasive Haemophilus influenzae infections after 3 decades of Hib protein conjugate vaccine use. Clin Microbiol Rev. 2021;34(3):e0002821.  https://doi.org/10.1128/CMR.00028-21 
  2. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). The National Immunisation Programme in the Netherlands. Surveillance and developments in 2023-2024. Bilthoven: RIVM; 2024. Available from: https://www.rivm.nl/bibliotheek/rapporten/2024-0072.pdf
  3. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Vaccinatiegraad Rijksvaccinatieprogramma Nederland. Verslagjaar 2025. [Vaccination coverage National Immunisation Programme in the Netherlands 2025]. Bilthoven: RIVM; 2025. Dutch. Available from: https://www.rivm.nl/publicaties/vaccinatiegraad-rijksvaccinatieprogramma-nederland-verslagjaar-2025
  4. Monge S, Hahné SJ, de Melker HE, Sanders EA, van der Ende A, Knol MJ. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study. Lancet Infect Dis. 2018;18(7):749-57.  https://doi.org/10.1016/S1473-3099(18)30166-X 
  5. Knuf M, Haas H, Garcia-Corbeira P, Turriani E, Mukherjee P, Janssens W, et al. Hexavalent vaccines: What can we learn from head-to-head studies? Vaccine. 2021;39(41):6025-36.  https://doi.org/10.1016/j.vaccine.2021.08.086 
  6. Pluijmaekers AJM, Steens A, Houweling H, Rots NY, Benschop KSM, van Binnendijk RS, et al. A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements. Vaccine X. 2024;20:100556.  https://doi.org/10.1016/j.jvacx.2024.100556 
  7. Steens A, Stanoeva KR, Knol MJ, Mariman R, de Melker HE, van Sorge NM. Increase in invasive disease caused by Haemophilus influenzae b, the Netherlands, 2020 to 2021. Euro Surveill. 2021;26(42):2100956.  https://doi.org/10.2807/1560-7917.ES.2021.26.42.2100956 
  8. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021;3(6):e360-70.  https://doi.org/10.1016/S2589-7500(21)00077-7 
  9. Shaw D, Abad R, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, et al. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health. 2023;5(9):e582-93.  https://doi.org/10.1016/S2589-7500(23)00108-5 
  10. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). The National Immunisation Programme in the Netherlands. Surveillance and developments in 2022-2023.; 2023. Available from: http://dx.doi.org/10.21945/RIVM-2023-0330
  11. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219.  https://doi.org/10.1136/bmj.326.7382.219 
  12. O’Loughlin RE, Edmond K, Mangtani P, Cohen AL, Shetty S, Hajjeh R, et al. Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: Systematic review. Vaccine. 2010;28(38):6128-36.  https://doi.org/10.1016/j.vaccine.2010.06.107 
  13. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis. 2003;188(4):481-5.  https://doi.org/10.1086/376997 
  14. McVernon J, Andrews N, Slack MPE, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet. 2003;361(9368):1521-3.  https://doi.org/10.1016/S0140-6736(03)13171-6 
  15. Hong E, Terrade A, Denizon M, Aouiti-Trabelsi M, Falguières M, Taha MK, et al. Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules. BMC Infect Dis. 2021;21(1):715.  https://doi.org/10.1186/s12879-021-06440-w 
  16. Deghmane A-E, Taha M-K. Changes in Invasive Neisseria meningitidis and Haemophilus influenzae Infections in France during the COVID-19 Pandemic. Microorganisms. 2022;10(5):907.  https://doi.org/10.3390/microorganisms10050907 
  17. Marques JG, Inácio Cunha FM, Bajanca-Lavado MP. Haemophilus influenzae Type b Vaccine failure in Portugal: a nationwide multicenter pediatric survey. Pediatr Infect Dis J. 2023;42(9):824-8.  https://doi.org/10.1097/INF.0000000000004011 
  18. European Centre for Disease Prevention and Control (ECDC). Surveillance atlas of infectious diseases. Stockholm: ECDC. [Accessed: 12 Aug 2025].Available from: https://atlas.ecdc.europa.eu/public/index.aspx
  19. Slack M, Esposito S, Haas H, Mihalyi A, Nissen M, Mukherjee P, et al. Haemophilus influenzae type b disease in the era of conjugate vaccines: critical factors for successful eradication. Expert Rev Vaccines. 2020;19(10):903-17.  https://doi.org/10.1080/14760584.2020.1825948 
  20. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). The National Immunisation Programme in the Netherlands. Surveillance and developments in 2021-2022. Bilthoven: RIVM; 2022. Available from: https://www.rivm.nl/bibliotheek/rapporten/2022-0042.pdf
  21. Bajanca-Lavado MP, Cavaco L, Fernandes M, Touret T, Candeias C, Simões AS, et al. Haemophilus influenzae carriage among healthy children in Portugal, 2015-2019. Microorganisms. 2022;10(10):1964.  https://doi.org/10.3390/microorganisms10101964 
  22. Giufrè M, Daprai L, Cardines R, Bernaschi P, Ravà L, Accogli M, et al. Carriage of Haemophilus influenzae in the oropharynx of young children and molecular epidemiology of the isolates after fifteen years of H. influenzae type b vaccination in Italy. Vaccine. 2015;33(46):6227-34.  https://doi.org/10.1016/j.vaccine.2015.09.082 
  23. van Werkhoven CH, de Gier B, McDonald SA, de Melker HE, Hahné SJM, van den Hof S, et al. Informed consent for national registration of COVID-19 vaccination caused information bias of vaccine effectiveness estimates mostly in older adults: a bias correction study. J Clin Epidemiol. 2024;174:111471.  https://doi.org/10.1016/j.jclinepi.2024.111471 
Product- and schedule-specific vaccine effectiveness against invasive Haemophilus influenzae serotype b (Hib) disease, The Netherlands, 2005 to 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Marta+Bertran&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bertran Marta</a>, <a href="/search?value1=Brechje+de+Gier&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Gier Brechje</a>, <a href="/search?value1=Tatiana+Garcia+Vilaplana&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Garcia Vilaplana Tatiana</a>, <a href="/search?value1=Nina+M+van+Sorge&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van Sorge Nina M</a>, <a href="/search?value1=Hester+E+de+Melker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Melker Hester E</a>, <a href="/search?value1=Anneke+Steens&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Steens Anneke</a></span>. Product- and schedule-specific vaccine effectiveness against invasive Haemophilus influenzae serotype b (Hib) disease, The Netherlands, 2005 to 2023. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(19):pii=2500699. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.19.2500699" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.19.2500699</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 09 Aug 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 02 Mar 2026 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.19.2500699
/content/10.2807/1560-7917.ES.2026.31.19.2500699
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error